Maxcyte (MXCT) Operating Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Expenses data on file, last reported at $14.3 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $14.3 million, down 32.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.8 million (down 12.14% YoY), and the FY2025 annual result was $78.7 million, down 4.86% from the prior year.
• Operating Expenses eased to $14.3 million in Q1 2026 per MXCT's latest filing, from $16.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $22.2 million in Q1 2024 and troughed at $14.3 million in Q1 2026.
• A 5-year average of $19.2 million and a median of $20.3 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses jumped 60.38% in 2022, then tumbled 32.66% in 2026.
• A 5-year view of Operating Expenses shows it stood at $17.6 million in 2022, then increased by 25.87% to $22.2 million in 2023, then slipped by 12.96% to $19.3 million in 2024, then dropped by 12.41% to $16.9 million in 2025, then slipped by 15.66% to $14.3 million in 2026.
• Business Quant data shows MXCT's Operating Expenses at $14.3 million in Q1 2026, $16.9 million in Q4 2025, and $19.4 million in Q3 2025.